Swiss National Bank Decreases Stock Holdings in AbbVie Inc. $ABBV

Swiss National Bank reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 4.9% in the third quarter, HoldingsChannel reports. The institutional investor owned 5,091,810 shares of the company’s stock after selling 263,000 shares during the quarter. AbbVie makes up approximately 0.7% of Swiss National Bank’s holdings, making the stock its 21st biggest holding. Swiss National Bank’s holdings in AbbVie were worth $1,178,958,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ABBV. Norges Bank bought a new position in shares of AbbVie during the second quarter valued at about $4,288,200,000. Laurel Wealth Advisors LLC grew its stake in shares of AbbVie by 18,384.4% in the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after purchasing an additional 5,675,095 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after purchasing an additional 3,380,842 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in AbbVie by 169.3% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock valued at $876,662,000 after purchasing an additional 2,969,202 shares during the period. Finally, Raymond James Financial Inc. raised its position in AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $230.41 on Monday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market capitalization of $407.40 billion, a P/E ratio of 97.63, a P/E/G ratio of 0.80 and a beta of 0.34. The stock has a 50 day moving average price of $224.72 and a 200-day moving average price of $224.21.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is 293.22%.

Insider Transactions at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ABBV has been the subject of several research analyst reports. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and increased their price objective for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Barclays assumed coverage on AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price for the company. Evercore dropped their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Finally, Scotiabank assumed coverage on shares of AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.